Microscopic resection margin status in pancreatic ductal adenocarcinoma - A nationwide analysis.


Journal

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
ISSN: 1532-2157
Titre abrégé: Eur J Surg Oncol
Pays: England
ID NLM: 8504356

Informations de publication

Date de publication:
03 2021
Historique:
received: 02 10 2020
revised: 19 11 2020
accepted: 28 11 2020
pubmed: 17 12 2020
medline: 15 9 2021
entrez: 16 12 2020
Statut: ppublish

Résumé

First, this study aimed to assess the prognostic value of different definitions for resection margin status on disease-free survival (DFS) and overall survival (OS) in pancreatic ductal adenocarcinoma (PDAC). Second, preoperative predictors of direct margin involvement were identified. This nationwide observational cohort study included all patients who underwent upfront PDAC resection (2014-2016), as registered in the prospective Dutch Pancreatic Cancer Audit. Patients were subdivided into three groups: R0 (≥1 mm margin clearance), R1 (<1 mm margin clearance) or R1 (direct margin involvement). Survival was compared using multivariable Cox regression analysis. Logistic regression with baseline variables was performed to identify preoperative predictors of R1 (direct). 595 patients with a median OS of 18 months (IQR 10-32 months) months were analysed. R0 (≥1 mm) was achieved in 277 patients (47%), R1 (<1 mm) in 146 patients (24%) and R1 (direct) in 172 patients (29%). R1 (direct) was associated with a worse OS, as compared with both R0 (≥1 mm) (hazard ratio (HR) 1.35 [95% and confidence interval (CI) 1.08-1.70); P < 0.01) and R1 (<1 mm) (HR 1.29 [95%CI 1.01-1.67]; P < 0.05). No OS difference was found between R0 (≥1 mm) and R1 (<1 mm) (HR 1.05 [95% CI 0.82-1.34]; P = 0.71). Preoperative predictors associated with an increased risk of R1 (direct) included age, male sex, performance score 2-4, and venous or arterial tumour involvement. Resection margin clearance of <1 mm, but without direct margin involvement, does not affect survival, as compared with a margin clearance of ≥1 mm. Given that any vascular tumour involvement on preoperative imaging was associated with an increased risk of R1 (direct) resection with upfront surgery, neoadjuvant therapy might be considered in these patients.

Identifiants

pubmed: 33323293
pii: S0748-7983(20)31041-6
doi: 10.1016/j.ejso.2020.11.145
pii:
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

708-716

Informations de copyright

Copyright © 2020. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.

Auteurs

L A Daamen (LA)

Dept. of Surgery, Regional Academic Cancer Center Utrecht, UMC Utrecht Cancer Center & St. Antonius Hospital Nieuwegein, the Netherlands; Dept. of Radiation Oncology, UMC Utrecht Cancer Center, Utrecht, the Netherlands.

I W J M van Goor (IWJM)

Dept. of Surgery, Regional Academic Cancer Center Utrecht, UMC Utrecht Cancer Center & St. Antonius Hospital Nieuwegein, the Netherlands; Dept. of Radiation Oncology, UMC Utrecht Cancer Center, Utrecht, the Netherlands.

T J Schouten (TJ)

Dept. of Surgery, Regional Academic Cancer Center Utrecht, UMC Utrecht Cancer Center & St. Antonius Hospital Nieuwegein, the Netherlands.

G Dorland (G)

Dept. of Surgery, Regional Academic Cancer Center Utrecht, UMC Utrecht Cancer Center & St. Antonius Hospital Nieuwegein, the Netherlands; Dept. of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, the Netherlands.

S R van Roessel (SR)

Dept. of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, the Netherlands.

M G Besselink (MG)

Dept. of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, the Netherlands.

B A Bonsing (BA)

Dept. of Surgery, Leiden University Medical Center, Leiden, the Netherlands.

K Bosscha (K)

Dept. of Surgery, Jeroen Bosch Hospital, Den Bosch, the Netherlands.

L A A Brosens (LAA)

Dept. of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands.

O R Busch (OR)

Dept. of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, the Netherlands.

R M van Dam (RM)

Dept. of Surgery, Maastricht UMC+, Maastricht, the Netherlands.

A Fariña Sarasqueta (A)

Dept. of Pathology, Leiden University Medical Center, Leiden, the Netherlands; Dept. of Pathology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, the Netherlands.

S Festen (S)

Dept. of Surgery, OLVG, Amsterdam, the Netherlands.

B Groot Koerkamp (B)

Dept. of Surgery, Erasmus MC, Rotterdam, the Netherlands.

E van der Harst (E)

Dept. of Surgery, Maasstad Hospital, Rotterdam, the Netherlands.

I H J T de Hingh (IHJT)

Dept. of Surgery, Catharina Hospital, Eindhoven, the Netherlands.

M P W Intven (MPW)

Dept. of Radiation Oncology, UMC Utrecht Cancer Center, Utrecht, the Netherlands.

G Kazemier (G)

Dept. of Surgery, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands.

V E de Meijer (VE)

Dept. of Surgery, University of Groningen and University Medical Center Groningen, Groningen, the Netherlands.

V B Nieuwenhuijs (VB)

Dept. of Surgery, Isala, Zwolle, the Netherlands.

G M Raicu (GM)

Dept. of Pathology, Regional Academic Cancer Center Utrecht, UMC Utrecht Cancer Center & St. Antonius Hospital Nieuwegein, the Netherlands.

D Roos (D)

Dept. of Surgery, Reinier de Graaf Group, Delft, the Netherlands.

J M J Schreinemakers (JMJ)

Dept. of Surgery, Amphia Hospital, Breda, the Netherlands.

M W J Stommel (MWJ)

Dept. of Surgery, Radboud University Medical Center, Nijmegen, the Netherlands.

M F van Velthuysen (MF)

Dept. of Pathology, Erasmus MC, Rotterdam, the Netherlands.

J Verheij (J)

Dept. of Pathology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, the Netherlands.

H M Verkooijen (HM)

Imaging Division, University Medical Centre Utrecht, the Netherlands, Utrecht University, Utrecht, the Netherlands.

H C van Santvoort (HC)

Dept. of Surgery, Regional Academic Cancer Center Utrecht, UMC Utrecht Cancer Center & St. Antonius Hospital Nieuwegein, the Netherlands.

I Q Molenaar (IQ)

Dept. of Surgery, Regional Academic Cancer Center Utrecht, UMC Utrecht Cancer Center & St. Antonius Hospital Nieuwegein, the Netherlands. Electronic address: I.Q.Molenaar@umcutrecht.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH